PHAT
Price
$10.88
Change
+$0.19 (+1.78%)
Updated
Jun 23, 04:14 PM (EDT)
Capitalization
852.59M
44 days until earnings call
Intraday BUY SELL Signals
XNCR
Price
$14.31
Change
+$0.30 (+2.14%)
Updated
Jun 23, 04:20 PM (EDT)
Capitalization
1.04B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PHAT vs XNCR

PHAT vs XNCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PHAT vs. XNCR commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAT is a StrongBuy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (PHAT: $10.69 vs. XNCR: $14.01)
Brand notoriety: PHAT and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAT: 53% vs. XNCR: 155%
Market capitalization -- PHAT: $852.59M vs. XNCR: $1.04B
PHAT [@Biotechnology] is valued at $852.59M. XNCR’s [@Biotechnology] market capitalization is $1.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAT’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • PHAT’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAT’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 6 bullish TA indicator(s).

  • PHAT’s TA Score: 4 bullish, 5 bearish.
  • XNCR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than PHAT.

Price Growth

PHAT (@Biotechnology) experienced а -0.19% price change this week, while XNCR (@Biotechnology) price change was +14.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.89%.

Reported Earning Dates

PHAT is expected to report earnings on Aug 06, 2026.

XNCR is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Biotechnology (+7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($1.04B) has a higher market cap than PHAT($853M). XNCR YTD gains are higher at: -8.491 vs. PHAT (-35.564). PHAT has higher annual earnings (EBITDA): -90.89M vs. XNCR (-131.66M). XNCR has more cash in the bank: 445M vs. PHAT (181M). PHAT has less debt than XNCR: PHAT (166M) vs XNCR (175M). PHAT has higher revenues than XNCR: PHAT (205M) vs XNCR (97.4M).
PHATXNCRPHAT / XNCR
Capitalization853M1.04B82%
EBITDA-90.89M-131.66M69%
Gain YTD-35.564-8.491419%
P/E RatioN/AN/A-
Revenue205M97.4M210%
Total Cash181M445M41%
Total Debt166M175M95%
FUNDAMENTALS RATINGS
PHAT vs XNCR: Fundamental Ratings
PHAT
XNCR
OUTLOOK RATING
1..100
915
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
7245
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
n/a10

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHAT's Valuation (70) in the null industry is in the same range as XNCR (89) in the Biotechnology industry. This means that PHAT’s stock grew similarly to XNCR’s over the last 12 months.

PHAT's Profit vs Risk Rating (100) in the null industry is in the same range as XNCR (100) in the Biotechnology industry. This means that PHAT’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (98) in the Biotechnology industry is in the same range as PHAT (100) in the null industry. This means that XNCR’s stock grew similarly to PHAT’s over the last 12 months.

XNCR's Price Growth Rating (45) in the Biotechnology industry is in the same range as PHAT (72) in the null industry. This means that XNCR’s stock grew similarly to PHAT’s over the last 12 months.

XNCR's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for PHAT (100) in the null industry. This means that XNCR’s stock grew significantly faster than PHAT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHATXNCR
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
85%
Bullish Trend 12 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
PHAT
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CIMFX27.150.06
+0.22%
American Funds Income Fund of Amer 529F1
ASPIX39.39N/A
N/A
Alger Spectra I
GCFSX22.19N/A
N/A
Gabelli Global Financial Services C
LKEQX39.46N/A
N/A
LKCM Equity
TRMVX28.58N/A
N/A
SEI Large Cap Value F (SIMT)

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with QCLS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then QCLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
-1.75%
QCLS - PHAT
39%
Loosely correlated
-0.75%
ATRA - PHAT
36%
Loosely correlated
+5.86%
XNCR - PHAT
34%
Loosely correlated
+10.84%
DYN - PHAT
34%
Loosely correlated
+5.51%
SEPN - PHAT
33%
Loosely correlated
-3.70%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+10.84%
VCYT - XNCR
52%
Loosely correlated
-0.82%
KURA - XNCR
51%
Loosely correlated
+4.33%
VIR - XNCR
50%
Loosely correlated
+4.48%
RCUS - XNCR
49%
Loosely correlated
+12.01%
IDYA - XNCR
49%
Loosely correlated
+9.61%
More